

Cardiovascular effects of nicotine vs. cigarette smoke

Dr Konstantinos Farsalinos

Researcher

Onassis Cardiac Surgery Center, Greece

University of Patras, Greece

National School of Public Health, Athens-Greece



1st (and last) slide

- Please look at last year's presentation by Prof. Neil Benowitz

Cardiovascular effects of nicotine vs. cigarette smoke

Dr Konstantinos Farsalinos

Researcher

Onassis Cardiac Surgery Center, Greece

University of Patras, Greece

National School of Public Health, Athens-Greece



ΕΘΝΙΚΗ
ΣΧΟΛΗ
ΔΗΜΟΣΙΑΣ
ΥΓΕΙΑΣ
ΥΓΕΙΟΝΟΜΙΚΗ ΣΧΟΛΗ
ΑΘΗΝΩΝ 1929-1994

NATIONAL
SCHOOL
OF PUBLIC
HEALTH
ATHENS SCHOOL
OF HYGIENE 1929-1994

Emerging harm reduction (?) choices Tobacco heated products

Dr Konstantinos Farsalinos

Researcher

Onassis Cardiac Surgery Center, Greece

University of Patras, Greece

National School of Public Health, Athens-Greece



Tobacco heated products

An old story

Premier Cigarette





1998, RJ Reynolds launched Premier

Tobacco heated products

An old story

- Premier replaced by Eclipse



Tobacco heated products

New developments



Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

Tobacco heated products

New developments

- Tobacco companies: JTI, PMI, BAT
- Two of them (PMI-IQOS, BAT-Glo) are heating tobacco through a resistance (maximum 350°C and 240°C respectively)
- PMI: heats tobacco by penetrating the stick with a metal blade (heat source)
- BAT: heats the tobacco through resistors (heat source) surrounding the tobacco stick
- JTI product (Ploom TECH) is an e-cigarette with a tobacco cartridge at the mouth piece (indirect heating of tobacco by the aerosol passing through the cartridge)

Tobacco heated products marketing

- PMI launched product in Japan in late 2014
 - Market share > 14% in Japan
 - Available in about 30 countries
- JTI launched product in March 2016
 - Also available in Switzerland
- BAT launched product in late 2016
 - Market share 1.8% in Japan
 - Now in Canada, S. Korea, Switzerland, Russia

A lot of research

Almost all by the manufacturers

- Chemistry
- Toxicology
- Clinical

Chemistry


Table 8

3R4F reference cigarette mainstream smoke yields and THP1.0 emission yields for the nine TobReg priority constituents, presented on per-consumable and per-puff bases, with calculated reductions per puff.

Parameter	Unit	3R4F		THP1.0(T)			THP1.0 (M)		
		Mean per consumable	Mean per puff ^a	Mean per consumable	Mean per puff ^a	%Red ⁿ per puff	Mean per consumable	Mean per puff ^a	%Red ⁿ per puff
1,3-Butadiene	µg	108	11.1	BDL (0.029)	0.002	>99.9	BDL (0.029)	0.002	>99.9
Acetaldehyde	µg	2200	208	111	13.9	93.3	115	14.4	93.1
Acrolein	µg	157	14.9	2.22	0.278	98.1	2.50	0.313	97.9
Benzene	µg	78.6	8.08	NQ (0.056)	0.005	99.9	NQ (0.056)	0.005	99.9
Benzo[a]pyrene	ng	12.9	1.26	NQ (0.354)	0.037	97.1	0.356	0.045	96.5
CO	mg	32.0	2.99	NQ (0.223)	0.010	99.7	NQ (0.223)	0.015	99.5
Formaldehyde	µg	54.10	5.11	3.29	0.411	92.0	3.51	0.439	91.4
NNK	ng	281	26.6	6.61	0.826	96.9	5.32	0.665	97.5
NNN	ng	263	24.8	24.7	3.09	87.6	19.1	2.39	90.4
				Average	96.1		Average	96.2	

Glo
average > 95% reduction in toxic emissions

Chemistry





IQOS
average 90%
reduction in toxic
emissions

Chemistry

	Analytes	units (/cig or capsule)	3R4F(A)	NTV(B)	B/A ratio
Hoffmann analyte	TPM	mg	42.5	86.4	2.03
	Puff count	puffs	10.6	60.0	5.66
	Water	mg	15.5	15.1	0.974
	Nicotine	mg	1.92	1.15	0.600
	Carbon monoxide	mg	30.7	ND(<0.26)	<0.0085
	NNN	ng	249	ND(<6.0)	<0.024
	NAT	ng	250	ND(<12.0)	<0.0480
	NAB	ng	25.6	ND(<8.5)	<0.33
	NNK	ng	223	ND(<7.1)	<0.032
	Formaldehyde	μg	108	ND(<0.6)	<0.006
	Acetaldehyde	μg	1757	ND(<2.7)	<0.0015
	Acetone	μg	602	ND(<1.9)	<0.0032
	Acrolein	μg	177	ND(<0.4)	<0.002
	Propionaldehyde	μg	131	ND(<0.6)	<0.005
	Crotonaldehyde	μg	56.1	ND(<1.3)	<0.023
	Methyl Ethyl Ketone	μg	150	ND(<2.7)	<0.018
	α-Butyraldehyde	μg	83.7	ND(<0.6)	<0.007
	1,3-Butadiene	μg	99.4	ND(<22.2)	<0.223
	Isoprene	μg	912	ND(<95.7)	<0.105
	Acrylonitrile	μg	30.2	ND(<3.4)	<0.11
	Benzene	μg	105	ND(<6.1)	<0.058
	Toluene	μg	200	ND(<6.0)	<0.030
	Hydrogen Cyanide	μg	476	ND(<0.7)	<0.001
	Benz(a)pyrene	ng	18.7	ND(<0.2)	<0.01
	Hydroquinone	μg	84.6	ND(<0.82)	<0.010
	Resorcinol	μg	2.04	ND(<0.2095)	<0.103
	Catechol	μg	89.0	ND(<1.7125)	<0.0192
	Phenol	μg	12.6	ND(<0.76)	<0.060
	<i>m</i> -Cresol	μg	8.36	ND(<0.7025)	<0.0840
	<i>p</i> -Cresol	μg	2.95	ND(<0.3675)	<0.125
	<i>o</i> -Cresol	μg	3.45	ND(<0.545)	<0.158
	Ammonia	μg	31.8	8.22	0.258
	Nitric Oxide	μg	520	ND(<0.65)	<0.0013
	Total Oxides of Nitrogen	μg	561	ND(<1.10)	<0.00196
	Pyridine	μg	41.0	ND(<1.46)	<0.0356
	Quinoline	μg	0.494	ND(<0.27)	<0.65
	Styrene	μg	27.1	ND(<0.76)	<0.028
	1-Aminonaphthalene	ng	22.2	ND(<1.13)	<0.0509
	2-Aminonaphthalene	ng	14.5	ND(<1.17)	<0.0807
	3-Aminobiphenyl	ng	5.18	ND(<0.41)	<0.079
	4-Aminobiphenyl	ng	3.51	ND(<0.35)	<0.10
	Mercury	ng	5.63	ND(<1.93)	<0.343
	Lead	ng	31.6	ND(<6.48)	<0.205
	Cadmium	ng	113	ND(<7.17)	<0.0635
	Chromium	ng	NQ	ND(<3.40)	-
	Nickel	ng	ND	ND(<7.04)	-
	Beryllium	ng	ND	ND(<3.81)	-
	Cobalt	ng	NQ	ND(<1.15)	-
	Selenium	ng	ND	ND(<9.10)	-
	Arsenic	ng	8.62	ND(<3.78)	<0.439

Ploom-Tech
average > 95%
reduction in toxic
emissions

Clinical studies



Clinical confinement for 5 days
Comparison between continuous smoking and switch to THP product


Clinical studies

Table 4
Biomarkers of exposure, ratios of THS relative to CC.

Biomarkers	Ratio ^a % and CI THS (N = 81)/CC (N = 41)
NEQ (mg/g creat)	104.9 (92.0; 119.6)
Nicotine ^{b,c} (ng/mL)	112.9(91.3; 139.5)
Cotinine ^{b,c} (ng/mL)	111.0 (90.8; 135.7)
Total NNAL (pg/mg creat)	43.5 (39.3; 48.2)
Total NNN (pg/mg creat)	24.1 (17.7; 32.8)
COHb ^c (%)	23.5 (22.0; 25.0)
MHBMA (pg/mg creat)	8.4 (6.8; 10.2)
3-HPMA (ng/mg creat)	41.6 (37.7; 46.0)
S-PMA (pg/mg creat)	6.0 (5.2; 6.9)
Total 1-OHP (pg/mg creat)	44.3 (39.8; 49.4)
4-ABP (pg/mg creat)	14.9 (12.8; 17.4)
1-NA (pg/mg creat)	3.7 (3.1; 4.5)
2-NA (pg/mg creat)	11.5 (10.0; 13.3)
o-tol (pg/mg creat)	41.7 (36.0; 48.3)
CEMA (ng/mg creat)	13.2 (11.5; 15.0)
HEMA (pg/mg creat)	32.0 (27.1; 37.8)
3- HMPMA (ng/mg creat)	22.5 (20.1; 25.3)
Total 3-OH-B[a]P (fg/mg creat)	27.5 (23.2; 32.6)

Clinical confinement study
Comparison between continuous smoking, smoking cessation and
switch to THP product

Clinical studies



SA = smoking abstinence
THS = THP


Research replication

- Although science should not be discarded, a critical and very cautious approach is need due to the source of the information (manufacturers, tobacco industry)
- It is of outmost importance to replicate the studies, carefully reviewing the methodology, testing several puffing regimes, checking the accuracy of the reported values

Independent studies

- Mainly 3 independent studies have attempted to replicate manufacturer publications for 1 HnB product (IQOS)

Independent studies




Nicotine concentration (mg/g) in unused tobacco sticks of IQOS appear to be similar to tobacco cigarettes

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

Farsalinos et al. Nicotine Tob Res 2017

Independent studies




Lower nicotine levels (-30%) to the aerosol compared to
tobacco cigarette smoke

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

Farsalinos et al. Nicotine Tob Res 2017

Independent studies

Nicotine delivery to the aerosol (IQOS)



Independent studies

Table. Concentrations of 8 Volatile Organic Compounds, 16 Polycyclic Aromatic Hydrocarbons, 3 Inorganic Compounds, and Nicotine in Mainstream Aerosol and Temperature of the HNB IQOS Cigarette and Conventional Cigarettes

Analyzed Compound	HNB Cigarette		Conventional Cigarette		Proportion of the Chemical in HNB and Conventional Cigarettes, %
	Amount, Mean (SD)	No. of Replications for Each Assay	Amount, Mean (SD)	No. of Replications for Each Assay	
Volatile organic compounds, µg per cigarette ^a					
Acetaldehyde	133 (35)	5	610 ^b	1	22
Acetone	12.0 (12.9)	5	95.5 (13.5)	2	13
Acroleine	0.9 (0.6)	2	1.1	1	82
Benzaldehyde	1.2 (1.4)	5	2.4 (2.6)	2	50
Crotonaldehyde	0.7 (0.9)	5	17.4	1	4
Formaldehyde	3.2 (2.7)	5	4.3 (0.4)	2	74
Isovaleraldehyde	3.5 (3.1)	5	8.5 (10.8)	2	41
Propionaldehyde	7.8 (4.3)	5	29.6 (36.6)	2	26

Independent studies

Polycyclic aromatic hydrocarbons, ng per cigarette^c

Naphthalene	1.6 (0.5)	4	1105 (269)	7	0.1
Acenaphthylene	1.9 (0.6)	4	235 (39)	7	0.8
Acenaphthene	145 (54)	4	49 (9)	7	295
Fluorene	1.5 (0.6)	4	371 (56)	7	0.4
Anthracene	0.3 (0.1)	4	130 (18)	7	0.2
Phenanthrene	2.0 (0.2)	4	292 (44)	7	0.7
Fluoranthene	7.3 (1.1)	4	123 (18)	7	6
Pyrene	6.4 (1.1)	4	89 (15)	7	7
Benz[a]anthracene	1.8 (0.4)	4	33 (4.2)	7	6
Chrysene	1.5 (0.3)	4	48 (6.2)	7	3
Benzo[b]fluoranthene	0.5 (0.2)	4	24 (2.9)	7	2
Benzo[k]fluoranthene	0.4 (0.2)	4	4.3 (2.8)	7	9
Benzo[a]pyrene	0.8 (0.1)	4	20 (2.9)	7	4
Indeno[1,2,3-cd]pyrene	ND	4	NA	NA	NA
Benzo[ghi]perylene	ND	4	NA	NA	NA
Dibenzo[a,h]anthracene	ND	4	NA	NA	NA

Inorganics, ppm in the mainstream smoke^d



Carbon dioxide	2057 (522)	5	>2000	3	NA
Carbon monoxide	328 (76)	5	>2000	3	NA
NITRIC OXIDE	5.5 (1.5)	5	89.4 (71.6)	3	6

Other measures

Nicotine, µg per cigarette ^a	301 (213)	4	361	1	84
Temperature, °C	330 (10)	2	684 (197)	1	NA
Puff total count	12.6 (2.4)	32	13.3 (3.1)	6	NA

Independent studies

Acetaldehyde



Independent studies

	IQOS		Tobacco cigarette		% difference
Polycyclic aromatic hydrocarbons, ng per cigarette ^c					
Naphthalene	1.6 (0.5)	4	1105 (269)	7	0.1
Acenaphthylene	1.9 (0.6)	4	235 (39)	7	0.8
Acenaphthene	145 (54)	4	49 (9)	7	295

- PMI responded that this is not a listed HPHC, but this is not good enough justification
- Anything potentially toxic should be tested, irrespective of being listed in HPHC lists
- Limited data on toxicity of acenaphthene, but it is a PAH produced during high temperature carbonization – more studies are needed to verify the levels, source and reasons it is formed
- Aldehyde levels were low in IQOS but were unusually low in tobacco cigarettes

Independent studies


Table 2. Concentrations of tar, nicotine, CO and TSNAs in mainstream cigarette smoke and transfer rates of each component in iQOS (regular and menthol) and conventional combustion cigarettes (3R4F and 1R5F)

Element	Mainstream cigarette smoke				Transfer rate (%)			
	iQOS regular	iQOS menthol	3R4F	1R5F	iQOS regular	iQOS menthol	3R4F	1R5F
TPM (mg/cig)	44.0 ± 11.4	49.9 ± 8.6	36.9 ± 1.9	28.9 ± 2.3	—	—	—	—
Water (mg/cig)	33.1 ± 10.2	35.3 ± 8.3	10.1 ± 0.9	8.8 ± 1.1	—	—	—	—
Tar (mg/cig)	9.8 ± 3.0	13.4 ± 2.2	25.2 ± 1.5	19.2 ± 1.3	—	—	—	—
Nicotine (mg/cig)	1.1 ± 0.1	1.2 ± 0.1	1.7 ± 0.1	1.0 ± 0.1	23.4	23.5	11.3	11.5
CO (mg/cig)	0.44 ± 0.04	0.43 ± 0.04	33.0 ± 1.8	29.7 ± 1.7	—	—	—	—
TSNAs (ng/cig)								
NNN	19.2 ± 2.1	24.9 ± 3.5	311.1 ± 24.3	240.7 ± 6.6	20.3	24.7	16.4	14.2
NAT	34.0 ± 3.1	37.2 ± 3.9	246.4 ± 16.9	183.1 ± 6.0	34.1	39.4	18.3	20.1
NAB	4.5 ± 0.5	5.5 ± 0.6	30.4 ± 2.0	26.2 ± 0.5	80.3	211.5	46.8	57.0
NNK	12.3 ± 1.5	13.8 ± 2.6	250.4 ± 13.7	107.0 ± 5.0	24.1	23.7	47.1	26.0
Total of TSNA	70.0 ± 7.2	81.4 ± 10.4	838.2 ± 53.7	557.1 ± 15.7	27.9	31.4	21.9	18.2

Bekki et al. J UOEH 2017

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>


Independent studies



Bekki et al. J UOEH 2017

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

Exhaled carbon monoxide




Farsali

Farsalinos et al. (unpublished data)


Aldehydes in THP

Formaldehyde




Aldehydes in THP

Acetaldehyde




Aldehydes in THP

Acrolein




Aldehydes in THP

Propionaldehyde




Aldehydes in THP


Crotonaldehyde




Aldehydes in THP different puffing regimes




Aldehydes in THP different puffing regimes




Aldehydes in THP different puffing regimes



Aldehydes in THP different puffing regimes




Aldehydes in THP different puffing regimes




Aldehydes in THP

Comparing IQOS, tobacco cigarette and e-cigarette




Aldehydes in THP

Comparing IQOS, tobacco cigarette and e-cigarette




Aldehydes in THP


Comparing IQOS, tobacco cigarette and e-cigarette




Aldehydes in THP difference from tobacco cigarettes



Aldehydes in THP difference from tobacco cigarettes




Aldehydes in THP difference from tobacco cigarettes



Farsalinos, Leischow et al. under preparation for submission

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

Aldehydes in the environment



*$20m^3$ ventilation
volume/day*

Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>

THPs and heart disease risk?



University of California
San Francisco

Inhalation of Heat-Not-Burn Tobacco Aerosol Impairs Vascular Endothelial Function

Pooneh Nabavizadeh MD¹, Jiangtao Liu MD¹, Sharina Ibrahim BSc², Ronak Derakhshandeh MS¹, Matthew L. Springer PhD^{1,2,3}

Cardiovascular Research Institute¹, Division of Cardiology², and Center for Tobacco Control Research and Education³
University of California, San Francisco, San Francisco, California





SCIENTIFIC 2|0
SESSIONS 1|7

Heat-not-burn tobacco products may be 'not
so hot' at protecting blood vessel function

- Exposed rats (n=8/group) via nose cone to 15 seconds of iQOS aerosol, Marlboro cigarette mainstream smoke, or air 10 times over 5 min
- FMD was quantitated pre- and post-exposure by measuring femoral artery diameter with micro-ultrasound before and after 5 min of transient surgically induced ischemia
- **Results: Acute exposure to iQOS aerosol can substantially impair endothelial function in rats comparably to cigarette smoke**

THPs and heart disease risk?

4.5-fold
higher
levels



3 studies (2 independent) showed IQOS delivers 30% lower nicotine levels to the aerosol than tobacco cigarettes

FMD and acute nicotine intake

Journal of the American College of Cardiology
© 2002 by the American College of Cardiology
Published by Elsevier Science Inc.

Vol. 39, No. 2, 2002
ISSN 0735-1097/02/\$22.00
PII S0735-1097(01)01732-6

Endothelial Function

Contribution of Nicotine to Acute Endothelial Dysfunction in Long-Term Smokers

Thomas Neunteufel, MD,* Sandra Heher, MD,* Karam Kostner, MD,* Goran Mitulovic, PhD,†
Stephan Lehr,‡ Gholamali Khoschsorur, PhD,§ Rainer W. Schmid, PhD,† Gerald Maurer, MD, FACC,*
Thomas Stefenelli, MD, FACC*

Vienna and Graz, Austria

... nicotine (*NRT*) alone causes acute endothelial dysfunction, although to a lesser extent than smoking a cigarette of the same nicotine yield.

Clinical Science (2005) 109, 55–60 (Printed in Great Britain)

55

Effect of coffee on endothelial function in healthy subjects: the role of caffeine

... coffee exerts an acute unfavourable effect on the endothelial function in healthy adults... This effect might be attributed to caffeine, given that decaffeinated coffee was not associated with any change in the endothelial performance.

Chris M. PAPAMICHAEL, Konstantinos A. AZNAOURIDIS, Emmanouil N. KARATZIS,
Kalliopi N. KARATZI, Kimon S. STAMATELOPOULOS, Georgia YAMVAKOU,
John P. LEKAKIS and Myron E. MAVRIKAKIS
Vascular Laboratory, Department of Clinical Therapeutics, University of Athens, Alexandra Hospital, Athens 15561, Greece

Conclusions (1)

- HnB products are not absolutely safe
 - The presence of tobacco and the temperatures of heating (at least for 2 of them) result in the unavoidable emission of some potentially toxic compounds
- Manufacturers report exposure reductions from 85% to 99% (the latter for JTI product)
- Almost all scientific data is coming from the manufacturers
 - This is currently the biggest problem, related to the justified mistrust for the industry
- Currently available evidence suggest substantial reduction in toxins and reduction in biomarkers of exposure – but more evidence is needed, especially from independent sources

Conclusions (2)

- Other factors besides the safety/risk profile should be considered in assessing the public health effects of these products.
 - $\text{Public health impact}_{THP} = (\text{hazard}_{SM-THP} \times \text{smoking cessation}) - (\text{hazard}_{THP} \times \text{use among non-smokers})$
– $(\text{hazard}_{SM} \times \text{smoking initiation})$
- Other key issues:
 - Do they lead to sustained smoking cessation?
 - Are they promoted and used by never-smokers?
 - Is there a “gateway to smoking” effect?
- Eventually, it depends on whether tobacco harm reduction is considered an acceptable and viable additional tool to combat the smoking epidemic

Conclusions (3)

- Current evidence (verified in a small part by independent studies) support that THPs can be considered harm reduction products
- There is a risk-continuum among harm reduction products, with e-cigarettes (new-generation) emitting lower levels of toxins compared to THPs
 - The absolute difference in toxic emissions from tobacco cigarettes is much higher than the absolute difference between harm reduction products – smokers should make informed decisions
- THPs could be a viable option for smokers unable to quit by themselves or with medications or with e-cigarettes or with snus (where available)



Source: <https://www.industrydocuments.ucsf.edu/docs/xxbx0301>